PMC9093033_01
Individual data about the evolution of BFCRS score according to the cumulative number of tDCS sessions. Case 2, for whom catatonia severity was assessed using Kanner scale, is not shown in this figure. In black, the regression line of the scatter plot.
fpsyt-13-876834-g002.jpg
PMC9093033_01_fpsyt-13-876834-g002.jpg
F2
Data about relative evolution of BFCRS scores for each patient are summarized in Figure 2.
Effect of tDCS and other factors on BFCRS. Coefficient estimates of the general linear mixed model. TDCS regressor was expressed in number of sessions since the beginning of the course, meaning that each tDCS session resulted in a 0.45 decrease of BFCRS score. Time was expressed in days. For benzodiazepine and antipsychotic a proxy for concentration was computed (see section "Materials and Methods"). For comparability of estimate size, benzodiazepine regressor was expressed in centigram (10 mg) of diazepam equivalent while antipsychotic regressor was expressed centigram of chlorpromazine equivalent. Error bars represent standard errors of coefficient estimates. ***Statistically significant.
fpsyt-13-876834-g003.jpg
PMC9093033_01_fpsyt-13-876834-g003.jpg
F3
To isolate the effect of tDCS from the effect of other treatments (and especially lorazepam, which is the most used drug in catatonia), we included two other possible confounding factors aiming to capture the effect of benzodiazepines and antipsychotic drugs (Figure 3).